Glucose Administration Inhibits the Hepatic Activation of Gluconeogenesis Promoted by Insulin-induced Hypoglycemia

Sharize Betoni Galende¹, Oswaldo Custódio de Oliveira Neto², Leandro Freire dos Santos², Márcia Vardanega Peicher¹, Helenir Medri de Souza³ and Roberto Barbosa Bazotte⁴*

¹Unidade de Ensino Superior Ingá; Maringá - PR - Brasil. ²Bolsista de Iniciação Científica do CNPq. ³Universidade Estadual de Maringá; Maringá - PR – Brasil. ⁴Departamento de Ciências Fisiológicas; Universidade Estadual de Londrina; Londrina - PR - Brasil. ⁵Departamento de Farmácia e Farmacologia; Universidade Estadual de Maringá; Av. Colombo, 5790; 87020-900; Maringá - PR – Brasil

ABSTRACT

The activation of hepatic gluconeogenesis in male Wistar adult 6 h fasted rats during insulin-induced hypoglycemia (IIH) was previously demonstrated. In this study, the effects of intraperitoneal (ip) glucose (100 mg/kg) on the activation of liver gluconeogenesis during IIH was investigated. Thus, 6 h fasted rats that received ip regular insulin (1 U/kg) and 30 min later ip saline (Control group) or glucose (Experimental group) were compared. All the experiments were executed 60 min after insulin injection. The glycemia of Control and Experimental groups were not different (P > 0.05). To investigate gluconeogenesis, liver perfusion experiments were performed. The results demonstrated that excepting glycerol, livers from rats which received ip glucose showed lower (P < 0.05) gluconeogenesis from L-alanine, L-glutamine, L-lactate or L-alanine + L-glutamine + L-lactate + glycerol. Therefore, the absence of glucose recovery after the glucose administration was mediated, at least in part, by an inhibition of hepatic gluconeogenesis.

Key words: Hypoglycemia, glycemia recovery, hepatic metabolism, gluconeogenesis, ureagenesis

INTRODUCTION

Intensive insulin therapy prevents the development of the chronic complications of type 1 (DCCT, 1993) and type 2 diabetes (UKPDS, 1998). However, the rigorous glycemic control has been related with an increased incidence of insulin induced hypoglycemia (IIH) which is the major obstacle to the implementation of the intensive treatment (Davis and Alonso, 2004). On the other hand, considering that glucagon, the most important gluconeogenic (Bracht et al., 2002) and glycogenolytic hormone (Vardanega-Peicher et al., 2003) is very expensive and has less availability, glucose is the main antidote to treat IIH (Moore and Woollard, 2005). However, previous studies (Souza et al., 2001a,b) have shown that a single intraperitoneal (ip) administration of glucose during IIH did not promote glycemia recovery. However, these studies did not establish the mechanism by which glucose administration did not promote glycemia recovery. Since IIH stimulates liver gluconeogenesis (Borba-Murad et al., 1999; Davis et al., 1995; Gazola et al., 2007;
Souza et al., 1994; Souza et al., 1996) that helps to restore normal glycemia, this work investigated the effects of ip glucose administration on the activation of hepatic gluconeogenesis during IIH. In addition, to get further information about the influence of glucose administration on liver gluconeogenesis, the effects of glucose precursors that entered in different points of this metabolic pathway were compared.

MATERIALS AND METHODS

Male Wistar rats weighing 180-220 g were used. The animals were maintained until the day of the experiment with free access to food and water. The animals were food deprived from 8:00 a.m. The experiments started 6 h later, i.e. at 2:00 p.m. The manipulation of the animals followed the Brazilian law on the protection of animals.

The in vivo experiments were executed to characterize the blood glucose and insulin after an ip injection (1 U/kg) of regular insulin (Neosulin®). Blood was obtained from rats killed by decapitation. The values of insulinemia (Desbuquois and Aurbach, 1971) after insulin injection at 0, 30, 60, 180 and 240 min (n = 7) were 27.0 ± 5.3, 227.0 ± 39.0, 136.0 ± 26.4, 52.3 ± 9.4 and 28.9 ± 1.5 µU/ml, respectively. The values of glycemia (Bergmeyer and Bernt, 1974) after insulin injection at 0, 30, 60, 180 and 240 min (n = 7) were 5.8 ± 0.12, 2.8 ± 0.26, 2.5 ± 0.45, 3.4 ± 0.52 and 4.1 ± 0.28 mM, respectively. IIH was well-established 30 min after insulin injection and so this period of time was selected for ip administration of glucose (Experimental group) or an equal volume of saline (Control group). The dose of glucose, i.e., 100 mg/kg, simulated the amount injected to treat IIH in human (Moore and Woollard, 2005).

Glycemia 60 min after insulin administration to Experimental group and Control group were 3.39 ± 0.15 (n = 15) and 3.25 ± 0.18 mM (n = 15), respectively (P > 0.05 vs. Control group).

The hepatic glucose production from L-lactate (Table lB) in livers of Experimental group was decreased (P < 0.05) whereas the hepatic pyruvate production was increased (P < 0.05). Livers of Experimental group also showed lower (P < 0.05) hepatic production of glucose from L-glutamine. But, the liver production of urea was not different (Table 1C). In contrast, livers from Experimental group showed higher (P < 0.05) glucose production from glycerol (Table 1D). Livers of IIH rats that received ip glucose, i.e., Experimental group, showed lower (P < 0.05) hepatic production of glucose from L-glutamine. But, the liver production of urea was not different (Table 1C). Finally, livers of rats that received glucose showed increased (P < 0.05) NADH-NAD ratio (8.32 ±
0.45 and 2.02 ± 0.18) for Experimental and Control group, respectively).

DISCUSSION

The failure of glucose administration to promote glucose recovery during IIH reaffirmed previous results (Souza et al., 2001a, b) and suggested that the injection of glucose showed limitation to treat IIH. However, studies showing the effect of glucose administration on the activation of liver gluconeogenesis during IIH are lacking. The effect of ip glucose administration on gluconeogenesis from livers of IIH rats is summarized in the Table 1.

The mechanism involved in the decreased hepatic glucose production from L-alanine, L-lactate and L-glutamine after glucose administration probably involves a blunt in the response to IIH mediated by counterregulatory hormones (Cryer, 1993; Davis et al., 1995). However, in contrast with L-alanine, L-lactate and L-glutamine, glucose production from glycerol (Table 1D), which entered in this metabolic pathway at the triose phosphate step, was increased (P < 0.05).

Livers from rats which received glucose showed higher basal L-lactate production (Figure 1B) and glycolysis probably was partly at least responsible for this, because it drive a greater fraction of the glucosyl units from glucose administered into the glycolytic pathway. Moreover, since it has been generally accepted that the ratio of L-lactate-pyruvate reflects the redox potential of the cytosolic NADH-NAD redox couple (Bazotte et al., 1990), and considering that the livers of rats that received glucose showed increased (P < 0.05) NADH-NAD ratio, it was hypothesize that this change in the cytosolic redox potential was not favorable for the conversion of L-alanine to glucose, as previously demonstrated in diabetic rats (Akimoto et al., 2000). The experimental group showed lower (P < 0.05) glucose production from L-alanine (Table 1A). In addition, the decreased catabolism of L-alanine, inferred by the lower (P < 0.05) L-lactate and urea production (Table 1A) could contribute to the lower hepatic glucose production from L-alanine in livers of Experimental group.

Table 1 - Area under curves (µmol/g) of glucose, pyruvate, L-lactate and urea from isolated or combined L-alanine (5 mM), L-lactate (2 mM), L-glutamine (5 mM) and glycerol (2 mM) in livers of Control and Experimental 6 h fasted rats. The livers were perfused as described in Figure 1. The data are reported as means ± SEM (5 rats per group).

<table>
<thead>
<tr>
<th></th>
<th>Control Group</th>
<th>Experimental Group</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>(A) L-alanine (L-ala)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Glucose</td>
<td>2.33 ± 0.08</td>
<td>0.84 ± 0.12*</td>
</tr>
<tr>
<td>Pyruvate</td>
<td>4.59 ± 0.76</td>
<td>4.12 ± 0.66</td>
</tr>
<tr>
<td>L-Lactate</td>
<td>7.64 ± 0.59</td>
<td>4.23 ± 0.63*</td>
</tr>
<tr>
<td>Urea</td>
<td>77.44 ± 1.94</td>
<td>68.07 ± 1.65*</td>
</tr>
<tr>
<td><strong>(B) L-lactate (L-lac)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Glucose</td>
<td>2.48 ± 0.23</td>
<td>1.46 ± 0.03*</td>
</tr>
<tr>
<td>Pyruvate</td>
<td>4.99 ± 0.11</td>
<td>6.65 ± 0.53*</td>
</tr>
<tr>
<td><strong>(C) L-glutamine (L-glut)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Glucose</td>
<td>11.67 ± 0.76</td>
<td>6.15 ± 0.70*</td>
</tr>
<tr>
<td>Urea</td>
<td>9.06 ± 0.59</td>
<td>8.90 ± 0.48</td>
</tr>
<tr>
<td><strong>(D) Glycerol (Gly)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Glucose</td>
<td>5.85 ± 0.40</td>
<td>8.43 ± 0.18*</td>
</tr>
<tr>
<td><strong>(E) L-ala + L-lac + L-glut + Gly</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Glucose</td>
<td>19.22 ± 0.68</td>
<td>15.59 ± 0.34*</td>
</tr>
<tr>
<td>Urea</td>
<td>13.18 ± 0.67</td>
<td>11.16 ± 0.65</td>
</tr>
</tbody>
</table>
Since the ability of L-alanine to produce glucose was limited by its decreased catabolism, L-lactate that entered in the gluconeogenic pathway at pyruvate step (Figure 2), was employed. As shown in Table 1B, livers from the Experimental group exhibited lower (P < 0.05) glucose production from L-lactate. Taken together, the results from L-alanine and L-lactate suggested that the gluconeogenesis until pyruvate step was decreased in the Experimental group. Furthermore, this metabolic change could be expanded until α-ketoglutarate step (Figure 2) since lower (P < 0.05) glucose production from L-glutamine was observed (Table 1C).

The results previously described were condensed in the Figure 2. Starting with L-alanine and L-lactate that entered in the gluconeogenic pathway at pyruvate step, the present results suggested that the treatment with glucose inhibited gluconeogenesis until pyruvate carboxylase (PC) step. In addition, the hepatic glucose production from L-glutamine, which entered in the gluconeogenic pathway after the PC step, was also inhibited (Table 1C). However, gluconeogenesis was not totally inhibited since the glucose production from glycerol which entered in this metabolic pathway after the PC and phosphoenolpyruvate carboxykinase (PEPCK) step was higher in the Experimental group (Table 1D).

In agreement with the results shown here and previous data (Souza et al., 2001b) lower (P < 0.05) hepatic glucose production was found from combined infusion of L-alanine, L-lactate, L-glutamine and glycerol in livers of Experimental group (Table 1E).

Thus, it could be concluded that the administration of glucose did not promote glycemia recovery, partly at least due to the inhibition of hepatic gluconeogenesis.
It must be emphasized that these results have clinical significance considering that oral (Marian et al., 2003) or parenteral (Moore and Woollard, 2005) glucose administration is mandatory in the prehospital management of hypoglycemia.

**Figure 2** - Gluconeogenesis in the hepatocyte. Plasma membrane is represented by the greatest rectangle and mitochondria by the smallest rectangle. + Increased gluconeogenesis, − Decreased gluconeogenesis. Abbreviations: AcCoA, acetyl-CoA; ASP, aspartate; CIT, citrate; AG, fatty acid; FDP, fructose diphosphate; F6P, fructose 6-phosphate; FUM, fumarate; GAP, glyceraldehyde phosphate; G6P, glucose 6-phosphate; α-KG, α-ketoglutarate; L-Glut, L-glutamine; PYR, pyruvate; MAL, malate; OAA, oxaloacetate; PEP, phosphoenolpyruvate; 2PG, 2-phosphoglycerate; 3PG, 3-phosphoglycerate; SUCC, succinate.

**ACKNOWLEDGEMENTS**

The authors are grateful to Mr. Carlos Eduardo de Oliveira and Solidalva Caruso de Oliveira for their technical assistance. We are grateful to Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), Fundação Araucária, Unidade de Ensino Superior Ingá and Instituto Nacional de Obesidade e Diabetes (CNPq) for financial support.

**RESUMO**

Em estudo recente empregando ratos Wistar com 6 h de privação alimentar demonstramos que ocorre ativação da neoglicogênese hepática durante a hipoglicemia induzida por insulina (HII). Neste estudo, os efeitos da administração intraperitoneal (ip) de glicose (100 mg/kg) sobre a ativação da neoglicogênese hepática durante a HII foi investigada. Assim, ratos com 6 h de privação alimentar que receberam insulina regular ip (1 U/kg) e 30 min depois salina (Grupo Controle) ou glicose ip (Grupo Experimental) foram comparados. Os experimentos foram executados 60 min após a injeção de insulina. A glicemia dos grupos Controle e Experimental não foi diferente (P > 0.05). Para investigar a neoglicogênese, realizou-se experimentos de perfusão de fígado. Os resultados demonstraram, exceto para o glicerol, que fígados de ratos que receberam glicose ip (Grupo Experimental), apresentaram menor taxa (P < 0.05) de neoglicogênese a partir de L-alanina, L-glutamina, L-lactato ou L-alanina + L-glutamina + L-lactato + glicerol. Portanto, a ausência de recuperação da glicemia após administração de glicose foi mediada por inibição da neoglicogênese hepática.
REFERENCES


Received: February 13, 2007;
Revised: August 24, 2007;
Accepted: November 11, 2008